These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 36099874)
1. Discordance in receptor status between primary and metastatic breast cancer and overall survival: A single-center analysis. Mellouli M; Graja S; Kridis WB; Ayed HB; Makni S; Triki M; Charfi S; Khanfir A; Boudawara TS; Kallel R Ann Diagn Pathol; 2022 Dec; 61():152044. PubMed ID: 36099874 [TBL] [Abstract][Full Text] [Related]
2. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases. Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555 [No Abstract] [Full Text] [Related]
3. Discordances in ER, PR and HER2 receptors between primary and recurrent/metastatic lesions and their impact on survival in breast cancer patients. Yang YF; Liao YY; Yang M; Peng NF; Xie SR; Xie YF Med Oncol; 2014 Oct; 31(10):214. PubMed ID: 25216864 [TBL] [Abstract][Full Text] [Related]
4. Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival. Schwieger L; Postlewait LM; Liu Y; Jou S; Yi S; Peng L; Li X Breast Cancer Res Treat; 2024 Sep; 207(2):373-382. PubMed ID: 38780889 [TBL] [Abstract][Full Text] [Related]
5. Retrospective analysis of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER2), Ki67 changes and their clinical significance between primary breast cancer and metastatic tumors. Qi G; Zhang X; Gai X; Yan X PeerJ; 2024; 12():e17377. PubMed ID: 38766488 [TBL] [Abstract][Full Text] [Related]
6. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer. Erdem GU; Altundag K; Ozdemir NY; Sahin S; Demirci NS; Karatas F; Bozkaya Y; Aytekin A; Tasdemir V; Aslan AC; Sever AR; Zengin N J BUON; 2017; 22(2):365-376. PubMed ID: 28534357 [TBL] [Abstract][Full Text] [Related]
7. The Case to Case Comparison of Hormone Receptors and HER2 Status between Primary Breast Cancer and Synchronous Axillary Lymph Node Metastasis. Sujarittanakarn S; Himakhun W; Worasawate W; Prasert W Asian Pac J Cancer Prev; 2020 Jun; 21(6):1559-1565. PubMed ID: 32592349 [TBL] [Abstract][Full Text] [Related]
8. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075 [TBL] [Abstract][Full Text] [Related]
9. Receptor discordance and phenotype change in metastatic breast cancer. Kao JY; Tsai JH; Wu TY; Wang CK; Kuo YL Asian J Surg; 2021 Jan; 44(1):192-198. PubMed ID: 32622530 [TBL] [Abstract][Full Text] [Related]
10. Prognostic Impact of Discordance in Hormone Receptor Status Between Primary and Recurrent Sites in Patients With Recurrent Breast Cancer. Shiino S; Kinoshita T; Yoshida M; Jimbo K; Asaga S; Takayama S; Tsuda H Clin Breast Cancer; 2016 Aug; 16(4):e133-40. PubMed ID: 27268749 [TBL] [Abstract][Full Text] [Related]
11. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study. Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130 [TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of estrogen, progesterone and HER2 receptors' status conversion following neoadjuvant chemotherapy in patients with locally advanced breast cancer: Results from a tertiary Cancer Center in Saudi Arabia. Al-Saleh K; Salah T; Arafah M; Husain S; Al-Rikabi A; Abd El-Aziz N PLoS One; 2021; 16(3):e0247802. PubMed ID: 33667252 [TBL] [Abstract][Full Text] [Related]
13. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer]. Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358 [No Abstract] [Full Text] [Related]
14. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment. Liu J; Deng H; Jia W; Zeng Y; Rao N; Li S; Jin L; Wu J; Song E; Su F J Cancer Res Clin Oncol; 2012 May; 138(5):837-42. PubMed ID: 22290394 [TBL] [Abstract][Full Text] [Related]
15. Profile and Outcome of Supraclavicular Metastases in Patients with Metastatic Breast Cancer: Discordance of Receptor Status Between Primary and Metastatic Site. Thangarajah F; Vogel C; Pahmeyer C; Eichler C; Holtschmidt J; Ratiu D; Mallmann P; Malter W Anticancer Res; 2018 Oct; 38(10):6023-6026. PubMed ID: 30275235 [TBL] [Abstract][Full Text] [Related]
16. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases. Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I J BUON; 2012; 17(2):277-83. PubMed ID: 22740206 [TBL] [Abstract][Full Text] [Related]
17. Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients. Aktas B; Kasimir-Bauer S; Müller V; Janni W; Fehm T; Wallwiener D; Pantel K; Tewes M; BMC Cancer; 2016 Jul; 16():522. PubMed ID: 27456970 [TBL] [Abstract][Full Text] [Related]
18. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Curtit E; Nerich V; Mansi L; Chaigneau L; Cals L; Villanueva C; Bazan F; Montcuquet P; Meneveau N; Perrin S; Algros MP; Pivot X Oncologist; 2013 Jun; 18(6):667-74. PubMed ID: 23723333 [TBL] [Abstract][Full Text] [Related]
19. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review. Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651 [TBL] [Abstract][Full Text] [Related]
20. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study. Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]